(19)
(11) EP 4 433 487 A1

(12)

(43) Date of publication:
25.09.2024 Bulletin 2024/39

(21) Application number: 22895109.1

(22) Date of filing: 20.11.2022
(51) International Patent Classification (IPC): 
C07H 19/09(2006.01)
A61K 47/54(2017.01)
A61K 31/7068(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07H 19/09; A61K 47/542
(86) International application number:
PCT/IL2022/051234
(87) International publication number:
WO 2023/089617 (25.05.2023 Gazette 2023/21)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 21.11.2021 US 202163281689 P

(71) Applicant: BioSight Ltd.
Lod 7019802 (IL)

(72) Inventors:
  • GENGRINOVITCH, Stela
    2010800 Kfar Hanania (IL)
  • LIDOR-HADAS, Ramy
    4424219 Kfar Saba (IL)
  • SHUMILOV, Margarita
    4649012 Herzliya (IL)

(74) Representative: Pearl Cohen Zedek Latzer Baratz UK LLP 
The Gridiron Building One Pancras Square
London N1C 4AG
London N1C 4AG (GB)

   


(54) CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER